<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Suzhou Ribo Life Science Co. Ltd. Class H — News on 6ix</title>
    <link>https://6ix.com/company/suzhou-ribo-life-science-co</link>
    <description>Latest news and press releases for Suzhou Ribo Life Science Co. Ltd. Class H on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 06 May 2026 11:20:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/suzhou-ribo-life-science-co" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo697f1621cfec6970aced0acf.webp</url>
      <title>Suzhou Ribo Life Science Co. Ltd. Class H</title>
      <link>https://6ix.com/company/suzhou-ribo-life-science-co</link>
    </image>
    <item>
      <title>Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)</title>
      <link>https://6ix.com/company/suzhou-ribo-life-science-co/news/ribo-and-boehringer-ingelheim-further-progress-their-sirna-program-for-metabolic-dysfunction-associated-steatohepatitis-mash</link>
      <guid isPermaLink="true">https://6ix.com/company/suzhou-ribo-life-science-co/news/ribo-and-boehringer-ingelheim-further-progress-their-sirna-program-for-metabolic-dysfunction-associated-steatohepatitis-mash</guid>
      <pubDate>Wed, 06 May 2026 11:20:00 GMT</pubDate>
      <description>Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (&quot;Ribo&quot;, HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with Boehringer Ingelheim to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH).</description>
    </item>
    <item>
      <title>Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH</title>
      <link>https://6ix.com/company/suzhou-ribo-life-science-co/news/ribo-and-ribocure-announce-exclusive-global-licensing-agreement-with-madrigal-for-novel-sirna-therapeutics-targeting-mash</link>
      <guid isPermaLink="true">https://6ix.com/company/suzhou-ribo-life-science-co/news/ribo-and-ribocure-announce-exclusive-global-licensing-agreement-with-madrigal-for-novel-sirna-therapeutics-targeting-mash</guid>
      <pubDate>Wed, 11 Feb 2026 11:31:00 GMT</pubDate>
      <description>Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) (&quot;Ribo&quot;) and its subsidiary Ribocure Pharmaceuticals AB (&quot;Ribocure&quot;) today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (&quot;Madrigal&quot;) for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).</description>
    </item>
  </channel>
</rss>